Ticker: RLYB

Rallybio Corporation (NASDAQ: RLYB) has recently disclosed its quarterly financial results for the period ending March 31, 2025. The company is focused on developing therapies for severe and rare diseases, particularly in the area of complement dysregulation, hematology, and metabolic disorders. ...